Padigar Shyamanand Tantry, MD
Endocrinology, Diabetes & Metabolism · Florence, SCNPI 1326490335
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,072 of the $5,766 with a category attached, or 88.0%. It is spread thinly across 33 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,980, more than ten times the $152 reported in 2019.
Across 233 payments — averaging $24.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$922
- Xeris Pharmaceuticals, Inc.$564
- Lilly USA, LLC$406
- Insulet Corporation$376
- Novo Nordisk$298
- Amgen$281
- plus $3K from 27 others
What the payments were for
- Travel & lodging$66211%
- Food & beverage$5,07288%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 7 | $922 |
| Xeris Pharmaceuticals, Inc. | 33 | $564 |
| Lilly USA, LLC | 29 | $406 |
| Insulet Corporation | 13 | $376 |
| Novo Nordisk | 14 | $298 |
| Amgen(2 entities) | 12 | $281 |
| Cequr Corporation | 4 | $263 |
| Abbott | 12 | $249 |
| BETA Bionics, Inc. | 8 | $248 |
| Bayer | 9 | $218 |
| Sanofi-aventis U.S. LLC | 9 | $217 |
| Boehringer Ingelheim | 10 | $184 |
| Corcept Therapeutics | 9 | $179 |
| Dexcom, Inc. | 9 | $169 |
| Ascensia Diabetes Care US Inc. | 7 | $144 |
| Ascendis Pharma Endocrinology Inc | 7 | $143 |
| Recordati_rare_diseases_inc. | 7 | $130 |
| AstraZeneca | 1 | $125 |
| Novartis | 6 | $112 |
| Tandem Diabetes Care, Inc. | 5 | $100 |
| Nevro Corp. | 4 | $78 |
| Rhythm Pharmaceuticals, Inc. | 3 | $71 |
| AbbVie | 4 | $65 |
| Intuity Medical Inc | 2 | $36 |
| Radius Health, Inc. | 1 | $34 |
| Chiesi USA, Inc. | 1 | $28 |
| Companion Medical, Inc. | 1 | $27 |
| EUSA Pharma (US) LLC | 1 | $18 |
| Sequel Med Tech, LLC | 1 | $18 |
| Zealand Pharma US, Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Intra-sana Laboratories | 1 | $16 |
| Globus Medical | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$592
- Strensiq$125
- Kerendia$115
- TEPEZZA$107
How this compares
$5,766 in reported general payments places this provider in the 65th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 399 | $429,884 |
| MounjaroTirzepatide | 317 | $377,920 |
| JardianceEmpagliflozin | 217 | $198,307 |
| Tresiba Flextouch U-200Insulin Degludec | 90 | $110,073 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 147 | $100,764 |
| Tresiba Flextouch U-100Insulin Degludec | 163 | $92,984 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 32 | $83,287 |
| FarxigaDapagliflozin Propanediol | 66 | $63,064 |
| JanuviaSitagliptin Phosphate | 60 | $58,439 |
| TrulicityDulaglutide | 43 | $49,953 |
| RybelsusSemaglutide | 33 | $47,274 |
| Novolog FlexpenInsulin Aspart | 140 | $32,854 |
| Humalog Kwikpen U-100Insulin Lispro | 135 | $32,661 |
| Gvoke Hypopen 2-PackGlucagon | 42 | $31,394 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $29,641 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $298 | $512,558492 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $406 | $457,006459 claims |
| Boehringer IngelheimJardiance, Synjardy | $184 | $202,044228 claims |
| MerckJanuvia, Janumet Xr | $17 | $73,71972 claims |
| AstraZenecaFarxiga | $125 | $63,06466 claims |
| AbbVieSynthroid | $65 | $17,692201 claims |
| Sanofi-aventis U.S. LLCAdmelog, Apidra | $217 | $3,27927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Florence
- Gerald MieleFlorence$35K
- Francisco Barrera EchegoyenFlorence$6K
- Meenakshi PandeFlorence$5K
- Sonika MalikFlorence$4K
- Hany ShenoudaFlorence$3K
- Melissa Gonzalez LaraFlorence$3K
- Gauri DhirMyrtle Beach$417K
- Cory WhiteGreenville$413K
- Louis HaenelCharleston$377K
- Vonda CalcuttWalterboro$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.